Dynamix Pharmaceuticals Completes a $10M Series A Financing

Signs a Collaboration Deal with Teva Pharmaceutical Industries

05-Mar-2009 - Israel

Dynamix Pharmaceuticals announced that they have closed a $10 million financing round. The financing was led by Batsheva Elran, Founder and Managing Partner of Opal Ventures, as a Medica3 fund investment with Teva Pharmaceutical Industries Ltd.

Dynamix Pharmaceuticals, founded by Dr. Oren M. Becker, who serves as its President and CEO, also announced that it has signed a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. for the discovery and development of up to two of Dynamix drug candidates.

Under the terms of the agreement, Dynamix will be eligible to earn milestones based on the achievement of certain discovery, development, regulatory and commercial milestones. Dynamix will also receive tiered royalties on sales by Teva of the collaboration-developed product sales.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances